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Abstract
Background: Lymphadenectomy is performed to assess patient prognosis and to prevent metastasizing. Recently,
it was questioned whether lymph node metastases were capable of metastasizing and therefore, if
lymphadenectomy was still adequate. We evaluated whether the nodal status impacts on the occurrence of distant
metastases by analyzing a highly selected cohort of colon cancer patients.
Methods: 1,395 patients underwent surgery exclusively for colon cancer at the University of Lübeck between 01/
1993 and 12/2008. The following exclusion criteria were applied: synchronous metastasis, R1-resection, prior/
synchronous second carcinoma, age < 50 years, positive family history, inflammatory bowel disease, FAP, HNPCC,
and follow-up < 5 years. The remaining 421 patients were divided into groups with (TM+, n = 75) or without (TM-,
n = 346) the occurrence of metastasis throughout a 5-year follow-up.
Results: Five-year survival rates for TM + and TM- were 21% and 73%, respectively (p < 0.0001). Survival rates
differed significantly for N0 vs. N2, grading 2 vs. 3, UICC-I vs. -II and UICC-I vs. -III (p < 0.05). Regression analysis
revealed higher age upon diagnosis, increasing N- and increasing T-category to significantly impact on recurrence
free survival while increasing N-and T-category were significant parameters for the risk to develop metastases
within 5-years after surgery (HR 1.97 and 1.78; p < 0.0001).
Conclusions: Besides a higher T-category, a positive N-stage independently implies a higher probability to develop
distant metastases and correlates with poor survival. Our data thus show a prognostic relevance of
lymphadenectomy which should therefore be retained until conclusive studies suggest the unimportance of
lmyphadenectomy.
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Background
Colon cancer is one of the most common malignant
tumor entities in Europe and North America [1].
Patients with synchronous distant metastasis have a sig-
nificantly worse prognosis than patients diagnosed with
localized disease. Despite an increasing motivation to
undergo routine screening about 20% of all patients are
diagnosed at an advanced tumor stage with manifest
metastases (Union Internationale Contre le Cancer
(UICC) stage IV). These patients face a 5-year survival
rate of around 10% [2,3]. Approximately 40% of patients
who initially present without distant tumor growth
(UICC stage II and III) will later on suffer from local or
distant recurrence [4]. Unfortunately, it still remains
clinically impossible to individually predict which
patients are more likely to develop distant recurrence
after resection of the primary carcinoma.
Colon cancer is staged according to the American
Joint Committee of Cancer (AJCC) TNM staging system
which reflects tumor invasion, lymph node involvement
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nectomy has long been established as the standard
oncologic resection of colon cancer [5]. Hereby, the N-
category not only implies the possible indication for an
adjuvant treatment in colon cancer but also constitutes
an important prognostic factor: different groups have
shown a survival benefit for patients with UICC-III and
even -II if an extensive dissection and evaluation of har-
vested lymph nodes were performed [1,6,7]. In contrast,
other studies suggest that lymph node dissection might
be of minor or no prognostic impact and - potentially -
should be omitted: Wong et al. analyzed a cohort of
30,625 colon cancer patients and showed that survival
was not significantly different when a median of 6 ver-
sus 13 lymph nodes were dissected [8]. Based on an
analysis of 16,129 patients Hölzel et al. revealed that the
number of positive lymph nodes and occurrence of dis-
tant metastases do not correlate [3]. Furthermore, they
presented a conclusive statistical model suggesting that
lymph node metastases are not capable to set distant
metastases. Consequently, they concluded that lymph
node resection might be of less clinical importance than
currently considered and potentially reflect “overtreat-
ment” [3,9]. One could therefore speculate that similar
to the past development of clinical pathways for surgical
breast cancer treatment, lymph node resection in colon
cancer could soon be performed according to a sentinel
concept instead of comprehensive lymphadenectomy as
performed today [10].
While many studies do not distinguish between carci-
nomas of the rectum and the colon, both need to be
accounted as different entities regarding anatomic routs
of metastasizing, prognosis and therapeutic regimes. In
order to determine accurate prognosis and survival rates
we therefore considered it necessary to distinguish
between both entities and focused exclusively on colon
carcinomas in this study. Furthermore, we excluded
patients who might bias the analysis due to clinical fea-
tures known to impact on prognosis: e.g., pre-existing
chronic inflammatory bowel disease [11], hereditary col-
orectal cancer [12,13], and residual tumor tissue after
surgical resection [14].
Due to the strict selection of our patient cohort, this
study design not only allowed determining the most
influencing prognostic factors in a highly selected cohort
of colon cancer patients. It was furthermore possible to
evaluate the impact of a positive lymph node status on
the subsequent development of distant metastases and
survival outcome.
Methods
Patients
This study encompassed 1,395 patients who underwent
surgery for colon cancer at the Department of Surgery,
University Clinic Schleswig-Holstein, Campus Lübeck,
Germany, between January 1993 and December 2008.
Prospectively documented demographic, clinical and
follow-up data were obtained after patients’ informed
consent and in accordance to the approval of the local
Ethical Committee (#07-124). We excluded patients
from the cohort of 1,395 patients who had not com-
pleted an in-house follow-up of at least 5 years unless
an event of either death or diagnosis of metastasis
occurred. Thus, median follow-up for the entire collec-
tive was 73.6 months (range 1.1-215.5 months). In
addition, patients younger than 50 years and patients
with synchronous metastases were excluded. “Synchro-
nous metastasis” and “synchronous second carcinoma"-
were defined as the diagnosis of a distant metastasis or
second carcinoma together with or within a three-
month interval of the diagnosis of the primary colon
cancer. “Metachronous"was defined as an occurrence
after a period of three months postoperatively. Addi-
tional exclusion criteria known to bias data analysis
regarding metastasizing, survival and prognosis of
colon cancer were applied (Figure 1). Subsequently, we
categorized the remaining patients into those who did
develop distant metastasis (TM+, n = 75) or who did
not (TM-, n = 346) within a 5-year follow-up. UICC/
AJCC stages were defined according to the consensus
of 1997 [15].
Statistics
Continuous variables were expressed as mean ± stan-
dard deviation and categorical variables as percent. The
Kaplan-Meier curves for TM + vs. TM-, grading 1-3,
UICC stage I-IV, N-status 0-2 and right vs. left colon
were calculated and assessed for significance by the log-
rank test. The 5-year survival rates were estimated with
the Kaplan-Meier method. The 95% confidence intervals
and the p-values were based on an asymptotic approach
by using the standard normal distribution. In addition, a
Cox regression backwards selection model was used to
investigate the effect of clinical and demographic para-
meters upon recurrence free survival and the occurence
of metastasis. For this analysis, initially all variables (sex,
age, N-category, T-category, UICC-stage and tumor
grading) were taken into account and variables with the
highest p-value (for p > 0.1) were excluded subse-
quently. All results were considered significant with p <
0.05. All calculations were performed using SAS soft-
ware version 9.2.
Results
Patient cohorts
We identified 2,570 patients from our colorectal cancer
database who underwent surgery between January 1993
and December 2008. Of those, 1,395 were colon cancer
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a collective of 421 patients with 75 presenting with sub-
sequent, metachronous metastasis (TM+) and 346 with-
out (TM-) (Figure 1). Overall, ninety-six patients were
staged UICC I, 182 patients UICC II and 143 patients
UICC III. For N-stage, there were 278 patients with N0,
92 patients with N1 and 51 patients with N2. For tumor
grading, 11 patients presented with G1, 321 patients
with G2 and 89 patients with G3. When considering the
cohorts of TM + and TM-, both groups presented with
comparable clinico-pathological parameters except for
differences in T-category, N-category, UICC-stage and
age with a higher age in the TM- cohort (Table 1).
Survival analysis
Overall, the 5-year survival rates showed significant dif-
ferences between UICC stages I and II (p = 0.0001) and
between stages I and III (p = 0.0002, Table 2). Kaplan-
Meier survival estimation showed significant differences
for the three-group comparison of UICC-I, -II and -III
(Figure 2b).
The 5-year survival rates for N-categories were 66%
for N0 (95%CI 60-71%), 64% for N1 (95%CI 53-73%)
and 49% for N2 (95%CI 35-62%), respectively. A signifi-
cant difference was found for the comparison between
N0 vs. N2 (p = 0.023). In line with these results,
Kaplan-Meier survival estimation showed a significant
Figure 1 Exclusion criteria for patients who underwent surgery for Colon Cancer. The listed exclusion criteria were applied subsequently.
CRC: Colorectal cancer, FAP: Familial Adenomatous Polyposis, HNPCC: Heriditary Non-Polyposis Colon Cancer, Tis: Carcinoma in situ.
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N2 (Figure 2c and 2d).
The 5-year survival rates for tumor grading were 73%
for grading 1 (95%CI 37-90%), 67% for grading 2 (95%
CI, 61-72%) and 52% for grading 3 (95%CI 41-61%),
respectively, with a significant difference between grad-
ing 2 and 3 (p = 0.0113). The 5-year survival rates for
right vs. left colon were 59% (95%CI 52-65%) and 68%
(95%CI 61-74%) and did not differ significantly.
When considering the cohorts of TM + and TM-,
patients with TM- presented with a significantly higher
5-year survival rate (73%; 95%CI 68-77%) compared to
those with TM + (21%; 95%CI 13-31%), as expected (p
< 0.0001, Table 2). These results were reflected by
Kaplan-Meier survival estimation which showed signifi-
cant differences for group comparison of TM + versus
TM- (Figure 2a).
Recurrence free survival and metachronous metastases
In order to determine demographic and clinical para-
meters with significant impact on recurrence free
survival we performed a Cox regression backwards ana-
lysis taking sex, age, N-category, T-category, UICC-stage
and tumor grading into account. This revealed an
increasing T-category (HR = 1.84, p < 0.0001), increas-
ing N-category (HR = 1.26, p = 0.033) and male sex
(HR = 1.04, p = < 0.0001) as significant parameters with
a negative impact on recurrence free survival (Table 3).
Furthermore, we aimed to identify parameters influen-
cing the occurrence of distant metastases. Here, Cox
regression backwards selection revealed a significant
relevance of an increasing N-category (HR = 1.97, p =
0.0001) and an increasing T-category (HR = 1.78, p =
0.0028) for the occurrence of metachronous distant
metastases (Table 4).
Discussion
This study evaluates survival and probability for the
occurrence of metachronous colon cancer metastasis.
For the first time, such an analysis was performed in a
highly selected cohort of patients with sporadic colon
cancer that passed thorough exclusion criteria. Known
clinical parameters were confirmed to be of significant
impact for patients’ p r o g n o s i ss u c ha ss e x ,T -a n d
N-category. Furthermore, Cox regression analysis
Table 1 Demographic and clinical data for the cohort
which developed metastases within a 5-year interval
after primary resection (TM+) and which did not (TM-)
Variable TM + (n = 75) TM- (n = 346) p-value
Age [years (SD)] 68.7 (10.1) 71.5 (10.2) 0.0222
Sex 0.4453
female 35 (46.7%) 180 (52.0%)
male 40 (53.3%) 166 (48.0%)
Localization 0.7023
right 34 (45.3%) 168 (48.6%)
left 41 (54.7%) 178 (51.4%)
T-stage < 0.0001
1 2 (2.7%) 34 (9.8%)
2 4 (5.3%) 66 (19.1%)
3 55 (73.3%) 21 (60.1%)
4 14 (18.7%) 35 (10.0%)
N-stage < 0.0001
0 29 (38.7%) 249 (72.0%)
1 24 (32.0%) 68 (19.6%)
2 22 (29.3%) 29 (8.4%)
Grading
1 1 (1.3%) 10 (2.9%) 0.5098
2 55 (73.4%) 266 (76.9%)
3 19 (25.3%) 70 (20.2%)
UICC-stage < 0.0001
1 5 (6.7%) 91 (26.3%)
2 24 (32.0%) 158 (45.7%)
3 46 (61.3%) 97 (28.0%)
Continuous variables are expressed as mean (standard deviation) and
categorical variables as number (percent). SD: standard deviation. Significant
p-values are highlighted in bold
Table 2 5-year survival rates (SR) and statistical analyses
for comparison of distinct groups of colon cancer
patients.
Variable 5-year
SR
95%
CI
p-value
(comparison)
Metastasis
yes (TM
+)
73% 68-77% < 0.0001
no (TM-) 21% 13-31%
Grading
1 73% 37-90% 0,6578 (1 vs 2)
2 67% 61-72% 0.1449 (1 vs
3)
3 52% 41-61% 0.0113 (2 vs 3)
N-stage
0 66% 60-71% 0.7206 (0 vs 1)
1 64% 53-73% 0.0230 (0 vs
2)
2 49% 35-62% 0.0790 (1 vs 2)
UICC stage
I 80% 71-87% 0,0001 (I vs II)
II 59% 51-66% 0.0002 (I vs
III)
III 59% 50-66% 0.9928 (II vs III)
Localization
right 59% 52-65% 0.0512
left 68% 61-74%
“Metastasis"implies the occurrence of a distant metastasis within a 5-year
interval after primary surgery. 5-year SR: 5-year survival rate; 95% CI: 95%
confidence interval. a = 0.05. Significant p-values are highlighted in bold
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survival as well as a significant impact of N-category on
the risk to develop metachronous metastasis. Only few
other studies have performed Cox regression analyses
for the same endpoints “survival” and “metachronous
metastasis”. However, none of these studies was based
on a collective with such stringent inclusion criteria
[16,17].
Several studies have shownas u r v i v a lb e n e f i tf o r
patients with an extensive examination of lymph nodes
for both UICC II and UICC III stage cancers [1,6,7].
The current North American consensus and the Ger-
man AWMF guidelines demand at least 12 lymph nodes
to be retrieved and examined in order to accurately
determine the stage of colon cancer [18,19]. However,
besides the surgical technique the lymph node yield
depends on a variety of variables such as age, immune-
response, investigation techniques and tumor location
[20]. Despite earlier reports that prognosis improves
with increasing lymph node count, the relationship
between lymph node yield and survival is not under-
stood and may not be causal but merely statistical in
nature. There has been no proof so far that distant
metastases can derive from lymph node metastases. The
association of tumor-positive lymph nodes with the
occurrence of distant metastasis has so far been based
on statistical measures and the same accounts for
improved survival with an increase of lymph nodes dis-
sected. Still, adequate resection of lymph nodes is also
performed in order to control local recurrence as well,
especially in stage III colon cancer patients. Studies have
shown a survival benefit for patients undergoing com-
plete mesocolic excision which does not imply a particu-
lar number of resected lymph nodes but rather aims at
the most radical dissection of lymph nodes possibly
involved [21,22]. The detection of micro metastases and
its association with worse prognosis in terms of occur-
rence of distant metastases and survival may also not be
causal, especially since other studies described contra-
dictory results [23,24]. In fact, several in-vitro and in-
vivo studies support the idea that lymph node metas-
tases are themselves not lethal and that surgical lymph
node removal should be de-emphasized or omitted [9].
On the other hand, epithelial-mesenchymal transition
(EMT) of tumor cells, a process of great importance for
the development of distant metastases, is reversed in the
metastasis itself (mesenchymal-epithelial transition,
MET). After a certain time, cells at the invasive front of
the metastasis may repeatedly undergo EMT thus
emphasizing their ability to disseminate and metastasize
subsequently [25].
Currently, there are no randomized trials or meta-ana-
lyses demonstrating a survival benefit of an extensive
lymph node dissection in colon cancer. The relevance of
radical lymph node dissection has been questioned by
other authors [26] and for some tumor entities the
extent of radical lymph node dissection was diminished
on the basis of clinical studies [27,28]. Based on the
colon cancer cohort of the Tumor Registry Munich,
Hölzel et al. stated that the risk to develop distant
metastases does not correlate with the detection of posi-
tive lymph nodes [3]. They also concluded that positive
lymph nodes that were not dissected would not contri-
bute to a subsequent occurrence of distant metastases.
An important assumption in their conclusions was,
however, that a given tumor grows with a constant
kinetic. In contrast, our results revealed that besides T-
category, particularly N-category is an independent fac-
tor with significant impact on the formation of distant
metastases.
Figure 2 Kaplan Meier survival curves for the cohorts a) TM-
versus TM+, b) UICC-stage I versus II versus III, c) N-stage 0
versus 1 versus 2 and d) N-stage 0 vs. 2. Significance was
determined using logrank-test.
Table 3 Results of the Cox regression backwards
selection analysis for recurrence free survival within a 5-
year interval
Variable Hazard Ratio 95% CI p-value
sex 1.040 1.024-1.057 0.033
N-category 1.261 1.019-1.560 < 0.0001
T-stage 1.838 1.422-2.375 < 0.0001
Sex, age, N-stage, T-stage, UICC-stage and grading were taken into account.
The Hazard Ratio implies a decrease in risk for the female sex and an increase
in risk with each additional year of age and for an increase T-stage, given that
the other two variables remain constant
Table 4 Results of the Cox regression backwards
selection analysis for the occurrence of distant
metastases within a 5-year interval
Variable Hazard Ratio 95% CI p-value
N-stage 1.97 1.49-2.60 0.0001
T-stage 1.78 1.22-2.60 0.0028
Sex, age, N-stage, T-stage, UICC-stage and grading were taken into account.
The Hazard Ratio implies an increase in risk for an increase in N- and T-stage,
given that the other variable remains constant
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influence the prognosis of colon cancer. Residual tumor
mass (R1 or R2 resection) after removal of the primary
malignancy implies a significantly worse prognosis than
R0-resected cancers [14]. Inflammatory bowel disease
(IBD)-associated colon carcinomas have a worse out-
come than colon cancer in patients without IBD [11,29].
Also, hereditary colorectal cancer differs in its prognosis
from sporadic colorectal cancer [12,13]. Most studies
regarding outcome of colon cancer analyzed large
cohorts without exclusion of patients with clinical fea-
tures known to have an impact on prognosis. Wang et
al. excluded patients with prior malignancies, carcino-
mas located more distally than the recto-sigmoid and
those with a histology other than signet cell, mucinous
or adenocarcinomas and analyzed a collective of 24,477
CRC patients for lymph node yield and prognosis [30].
They did not exclude patients with potential hereditary
malignant disease or IBD. Hashiguchi et al. excluded
patients with multiple colon cancers, patients with
another synchronous malignancy and patients with a
diagnosed polyposis. They analyzed the prognostic sig-
nificance of the number of lymph nodes examined in
colon cancer and included 859 patients from a single
centre [31]. In our study we performed all analyses in a
thoroughly selected patient cohort thereby minimizing
the bias arising from a large but heterogeneous collec-
tive. Additionally, in order to address the issue of meta-
chronous distant metastases in relation to the status of
lymph nodes dissected during primary surgery we
excluded patients who had not completed a 5-year fol-
low-up. Patients who underwent primary resection of
colon cancer at a different center were also excluded in
order to eliminate possible inter-center variability of
patients’ prognosis [32].
We found significant differences in survival only for
some of the given categories within each parameter
such as the difference for N0 versus N2 and grading G2
versus G3. We have to acknowledge the possibility that
the lack of significant differences for all categories may
be due to the small size of our cohorts. On the other
hand, none of the studies showing significant differences
for all categories had patients as strictly selected. The
cohorts of TM + and TM- differed significantly in T-
category, N-category, UICC-stage and age. The differ-
ence in age might have biased the results. However,
since the TM- cohort was on average older while pre-
senting better survival we argue that the difference is
valid and might in fact be larger. The problem of differ-
ences in the other variables was addressed by Cox
regression analysis. Cox regression analysis showed that
T-category and N-category besides sex were parameters
with significant impact on 5-year recurrence free survi-
val. Generally, an increase in both N- and T-category is
known to be associated with worse prognosis [3]. Only
for the regression analysis we used recurrence free sur-
vival. For the calculation of survival curves we used
overall survival. We have to take into consideration that
in this context, analyses of overall survival certainly have
shortcomings in comparison to disease specific survival.
In order to avoid this dilemma, we limited the survival
comparisons to a 5-year interval by censoring all
patients with later events. For this period, we estimate
the mortality to be primarily related to the pre-existing
malignancy.
Our Cox regression analysis revealed that both N- and
T-category are parameters with significant impact on
the risk to develop distant metastases. Several studies
have performed Cox regression analyses with hazard
ratios given for each category, i.e. N1 versus N2 and
versus N3 [3]. Only a few studies included Cox regres-
sion analyses in order to determine which pathological
and demographic parameters have the highest impact
on the endpoints “death” and “occurrence of a meta-
chronous distant metastasis”. Ikeguchi et al. investigated
282 patients with regard to survival and occurrence of
metachronous metastases and a possible correlation
with various clinic-pathological and cytometric para-
meters [17]. Lymph node status, tumor location (rec-
tum/colon) and lymphatic invasion were significant
factors in logistic regression analysis affecting metachro-
nous hematogenic metastases whereas T-category and
ploidy status were not. However, the only exclusion cri-
terion for the collective was adjuvant chemo- or radio-
chemotherapy [17]. Heinzerling et al. analyzed 51 dis-
tinct clinicopathological parameters addressing the ques-
tion of metachronous metastasis occurrence [16]. In
their multivariate analysis only alcohol intake, patients
undergoing abdomino-perineal resection and the use of
angiotensin-converting enzyme inhibitor were signifi-
cantly associated with development of distant disease
relapse. In their univariate analysis, however, the dissec-
tion of fewer lymph nodes was associated with develop-
ment of metastasis. The study collective consisted of
only 55 patients with carcinoma of both the rectum and
the colon and 96% of the patients were males. UICC II
s t a g ew a st h eo n l yi n c l u s i o nc r i t e r i aa n df o l l o w - u pw a s
three years.
Conclusion
Much like previous studies we cannot provide any proof
for a causal association of lymph node status and a sub-
sequent metastasis. However, our regression analysis
shows that lymph node status is of independent prog-
nostic impact for the occurrence of distant metastasis in
colon cancer patients. In light of our study, previous
clinical studies and molecular investigations it is reason-
able to assume that lymph nodes are able to set distant
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tion of lymph nodes in patients with colon cancer
should be continued until further studies suggest
otherwise.
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